BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 35521769)

  • 1. Metastatic medullary thyroid carcinoma: a new way forward.
    Angelousi A; Hayes AR; Chatzellis E; Kaltsas GA; Grossman AB
    Endocr Relat Cancer; 2022 May; 29(7):R85-R103. PubMed ID: 35521769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
    Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
    Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
    Dabelić N; Jukić T; Fröbe A
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V; Kumar M; Chen AY; Owonikoko TK
    Cancer Treat Rev; 2016 Nov; 50():89-98. PubMed ID: 27664392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
    Saltiki K; Simeakis G; Karapanou O; Alevizaki M
    Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 7. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on C-Cell Neuroendocrine Neoplasm: Prognostic and Predictive Histopathologic and Molecular Features of Medullary Thyroid Carcinoma.
    Jung CK; Agarwal S; Hang JF; Lim DJ; Bychkov A; Mete O
    Endocr Pathol; 2023 Mar; 34(1):1-22. PubMed ID: 36890425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medullary Thyroid Cancer: Updates and Challenges.
    Gild ML; Clifton-Bligh RJ; Wirth LJ; Robinson BG
    Endocr Rev; 2023 Sep; 44(5):934-946. PubMed ID: 37204852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Evolving Treatment Landscape of Medullary Thyroid Cancer.
    Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
    Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
    Seib CD; Beck TC; Kebebew E
    Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of the art and future directions in the systemic treatment of medullary thyroid cancer.
    Jager EC; Broekman KE; Kruijff S; Links TP
    Curr Opin Oncol; 2022 Jan; 34(1):1-8. PubMed ID: 34669647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic medullary thyroid carcinoma (MTC): disease course, treatment modalities and factors predisposing for drug resistance.
    Saltiki K; Simeakis G; Karapanou O; Paschou SA; Alevizaki M
    Endocrine; 2023 Jun; 80(3):570-579. PubMed ID: 36626081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Advanced Medullary Thyroid Carcinoma: Current Systemic Therapy Options.
    Jara MA
    Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
    Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
    Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
    Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.